Back to Search
Start Over
Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
- Source :
-
Cancer genetics and cytogenetics [Cancer Genet Cytogenet] 2009 Feb; Vol. 189 (1), pp. 63-7. - Publication Year :
- 2009
- Subjects :
- Benzamides
Chromosomes, Human, Pair 21 genetics
Chromosomes, Human, Pair 8 genetics
Female
Humans
Imatinib Mesylate
Karyotyping
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative pathology
Middle Aged
RUNX1 Translocation Partner 1 Protein
Antineoplastic Agents therapeutic use
Core Binding Factor Alpha 2 Subunit genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Leukemia, Myeloid, Acute genetics
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative genetics
Oncogene Proteins, Fusion genetics
Piperazines therapeutic use
Pyrimidines therapeutic use
Translocation, Genetic genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1873-4456
- Volume :
- 189
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cancer genetics and cytogenetics
- Publication Type :
- Report
- Accession number :
- 19167615
- Full Text :
- https://doi.org/10.1016/j.cancergencyto.2008.09.016